A Systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: Rationale, Design, and Baseline Characteristics of BIOSTAT-CHF
Adriaan A. Voors(University Medical Center Groningen), Marco Metra(Vita-Salute San Raffaele University), Piotr Ponikowski(Wroclaw Medical University), Pim van der Harst(Utrecht University), Gerasimos Filippatos(National and Kapodistrian University of Athens), Hans L. Hillege(University Medical Center Groningen), Aeilko H. Zwinderman(Amsterdam Neuroscience), Chim C. Lang(University of Dundee), Dirk J. van Veldhuisen(University Medical Center Groningen), Jozine M. ter Maaten(University Medical Center Groningen), Leong L. Ng(University of Leicester), Nilesh J. Samani(University of Leicester), Kenneth Dickstein, F. Zannad(Inserm), Stefan D. Anker(Charité - Universitätsmedizin Berlin), John G.F. Cleland(University of Glasgow)
Cited by 204
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k